The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2015

Filed:

Apr. 29, 2014
Applicants:

Newlink Genetics Corporation, Ames, IA (US);

Lankeanau Institute for Medical Research, Wynnewood, PA (US);

Inventors:

Mario R. Mautino, Ankeny, IA (US);

Sanjeev Kumar, Ames, IA (US);

Firoz Jaipuri, Ames, IA (US);

Jesse Waldo, Huxley, IA (US);

Tanay Kesharwani, Lake Katrine, NY (US);

Nicholas N. Vahanian, Polk City, IA (US);

Charles J. Link, Clive, IA (US);

Judith Lalonde, Bryn Mawr, PA (US);

George Prendergast, Wynnewood, PA (US);

Alexander Muller, Wynnewood, PA (US);

William Malachowski, Bryn Mawr, PA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4174 (2006.01); C07D 233/64 (2006.01); C07D 233/56 (2006.01); C07D 233/58 (2006.01); C07D 233/60 (2006.01); C07D 233/61 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 417/06 (2006.01); C07D 498/04 (2006.01); C07H 19/067 (2006.01);
U.S. Cl.
CPC ...
C07D 233/64 (2013.01); A61K 31/4174 (2013.01); C07D 233/56 (2013.01); C07D 233/58 (2013.01); C07D 233/60 (2013.01); C07D 233/61 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 413/12 (2013.01); C07D 417/06 (2013.01); C07D 498/04 (2013.01); C07H 19/067 (2013.01);
Abstract

Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R, R, and Rare defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.


Find Patent Forward Citations

Loading…